PFHO Pacific Health Care Organization (PFHO) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0001138476
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about PFHO
Insiders, 180 days
+$90.0K net bought
1 buyer
Pacific Health Care Organization insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, PACIFIC HEALTH CARE ORGANIZATION INC insiders bought a net $90.0K of stock across 50 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 49 earlier Form 4 trades (code P or S) here by this insider (49 buys), the last on May 27, 2026.
- -6.9% median (-3.3% mean) 90-day return after 30 previous buys.
- The trade is 0.3% of the 8,500,000 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO & President KUBOTA TOM bought about $24.7K of PFHO on Jun 3, 2026.Context
- 48 earlier Form 4 trades (code P or S) here by this insider (48 buys), the last on Jun 26, 2024.
- -8.1% median (-3.9% mean) 90-day return after 30 previous buys.
- The trade is 0.8% of the 8,475,258 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO & President KUBOTA TOM bought about $65.3K of PFHO on May 27, 2026, the largest insider purchase at the company on our record.Context
- 44 earlier Form 4 trades (code P or S) here by this insider (44 buys), the last on Jun 24, 2024.
- -8.1% median (-3.9% mean) 90-day return after 30 previous buys.
- The trade is 0.0% of the 8,410,000 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO & President KUBOTA TOM bought about $2.5K of PFHO on Jun 26, 2024.Context
- 44 earlier Form 4 trades (code P or S) here by this insider (44 buys), the last on Jun 24, 2024.
- -8.1% median (-3.9% mean) 90-day return after 30 previous buys.
- The trade is 0.1% of the 8,407,501 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO & President KUBOTA TOM bought about $9.8K of PFHO on Jun 26, 2024.Context
- 44 earlier Form 4 trades (code P or S) here by this insider (44 buys), the last on Jun 24, 2024.
- -8.1% median (-3.9% mean) 90-day return after 30 previous buys.
- The trade is 0.1% of the 8,395,001 shares held after it.
- No other insider bought within 30 days.
Insider activity: CEO & President KUBOTA TOM bought about $5.6K of PFHO on Jun 26, 2024.50 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$90.0K over 180 days
+$90.0K of it by a 10%+ holder
more than 78% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+10.7% year over year
below 51% of Healthcare Services
Margin
20.7% net margin
more than 95% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
the lowest in Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PFHO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.3%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PFHO: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in PFHO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PFHO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $90.0K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
PFHO financials
Revenue growth
+10.7%
XBRL, annual
Net margin
20.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.4M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PFHO
| FY Dec 2025 | $6.7M |
| FY Dec 2024 | $6.0M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $5.7M |
| FY Dec 2021 | $5.4M |
| Jun 2026 | $1.8M |
| Mar 2026 | $1.5M |
| Dec 2025 | $1.6M |
| Sep 2025 | $1.6M |
| Jun 2025 | $1.7M |
| Mar 2025 | $1.8M |
| Dec 2024 | $1.5M |
| Sep 2024 | $1.5M |
At each fiscal year end
Single quarter
Net margin, TTM
+15.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PFHO
| FY Dec 2025 | +20.7% |
| FY Dec 2024 | +14.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +8.6% |
| FY Dec 2021 | +18.4% |
| Jun 2026 | +18.4% |
| Mar 2026 | +12.9% |
| Dec 2025 | +14.9% |
| Sep 2025 | +14.1% |
| Jun 2025 | +36.9% |
| Mar 2025 | +16.1% |
| Dec 2024 | +19.2% |
| Sep 2024 | +11.4% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$578.4K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PFHO
| FY Dec 2025 | $1.1M |
| FY Dec 2024 | $666.0K |
| FY Dec 2023 | $914.8K |
| FY Dec 2022 | $672.4K |
| FY Dec 2021 | $368.0K |
| Jun 2026 | -$9.8K |
| Mar 2026 | $228.0K |
| Dec 2025 | $337.2K |
| Sep 2025 | $23.0K |
| Jun 2025 | $455.1K |
| Mar 2025 | $322.2K |
| Dec 2024 | $566.3K |
| Sep 2024 | -$38.2K |
At each fiscal year end
Single quarter
Debt to equity
0.00x
current debt only, 2024-12-31 (18 months older than the period end); equity 2026-06-30
Debt to equity PFHO
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
16.93x
TTM operating cash flow over current debt only, 2024-12-31 (18 months older than the period end)
Cash flow to debt PFHO
| FY Dec 2025 | 32.88x |
| FY Dec 2024 | 19.12x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 16.93x |
| Mar 2026 | 29.97x |
| Dec 2025 | 32.88x |
| Sep 2025 | 39.02x |
| Jun 2025 | 37.31x |
| Mar 2025 | 20.25x |
| Dec 2024 | 19.12x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+7.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PFHO
| FY Dec 2025 | +11.2% |
| FY Dec 2024 | +7.9% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +4.5% |
| FY Dec 2021 | +9.6% |
| Jun 2026 | +7.5% |
| Mar 2026 | +10.2% |
| Dec 2025 | +11.2% |
| Sep 2025 | +12.0% |
| Jun 2025 | +11.7% |
| Mar 2025 | +8.5% |
| Dec 2024 | +7.9% |
| Sep 2024 | +7.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PFHO
| FY Dec 2025 | +10.7% |
| FY Dec 2024 | +7.3% |
| FY Dec 2023 | +6.5% |
| FY Dec 2022 | +4.2% |
| FY Dec 2021 | +8.9% |
| Jun 2026 | +7.1% |
| Mar 2026 | +9.8% |
| Dec 2025 | +10.7% |
| Sep 2025 | +11.4% |
| Jun 2025 | +11.1% |
| Mar 2025 | +7.9% |
| Dec 2024 | +7.3% |
| Sep 2024 | +7.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+6.2%
operating income after a 26.1% effective tax rate, over current debt only, 2024-12-31 (18 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PFHO
| FY Dec 2025 | +7.1% |
| FY Dec 2024 | +6.6% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +6.2% |
| Mar 2026 | +6.1% |
| Dec 2025 | +7.1% |
| Sep 2025 | +8.4% |
| Jun 2025 | +8.1% |
| Mar 2025 | +7.8% |
| Dec 2024 | +6.6% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+7.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PFHO
| FY Dec 2025 | +8.1% |
| FY Dec 2024 | +7.6% |
| FY Dec 2023 | +6.1% |
| FY Dec 2022 | +6.0% |
| FY Dec 2021 | +4.9% |
| Jun 2026 | +7.1% |
| Mar 2026 | +6.8% |
| Dec 2025 | +8.1% |
| Sep 2025 | +9.5% |
| Jun 2025 | +9.3% |
| Mar 2025 | +8.6% |
| Dec 2024 | +7.6% |
| Sep 2024 | +7.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
10.44x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PFHO
| FY Dec 2025 | 11.82x |
| FY Dec 2024 | 10.29x |
| FY Dec 2023 | 14.20x |
| FY Dec 2022 | 25.33x |
| FY Dec 2021 | 10.56x |
| Jun 2026 | 9.44x |
| Mar 2026 | 10.91x |
| Dec 2025 | 11.82x |
| Sep 2025 | 10.64x |
| Jun 2025 | 8.00x |
| Mar 2025 | 10.29x |
| Dec 2024 | 10.29x |
| Sep 2024 | 11.86x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$9.8M
market value at close 2026-10-26 on 2026-08-04 shares, plus current debt only, 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
Enterprise value PFHO
| FY Dec 2025 | $14.5M |
| FY Dec 2024 | $7.2M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $8.7M |
| Mar 2026 | $13.0M |
| Dec 2025 | $14.5M |
| Sep 2025 | $12.8M |
| Jun 2025 | $8.1M |
| Mar 2025 | $6.9M |
| Dec 2024 | $7.2M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield PFHO
| FY Dec 2025 | +6.8% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +10.1% |
| FY Dec 2022 | +6.9% |
| FY Dec 2021 | +3.0% |
| Jun 2026 | +5.3% |
| Mar 2026 | +6.8% |
| Dec 2025 | +6.8% |
| Sep 2025 | +9.1% |
| Jun 2025 | +12.7% |
| Mar 2025 | +7.6% |
| Dec 2024 | +7.2% |
| Sep 2024 | +5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -10%, PEG needs growth
PEG, trailing PFHO
| FY Dec 2025 | 0.21x |
| FY Dec 2024 | 0.26x |
| FY Dec 2023 | 0.21x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.08x |
| Jun 2026 | n/a |
| Mar 2026 | 0.19x |
| Dec 2025 | 0.21x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.19x |
| Mar 2025 | 0.62x |
| Dec 2024 | 0.26x |
| Sep 2024 | 0.09x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.7M | $6.1M | $5.6M | $5.7M |
| Operating income | $1.0M | $852.6K | $678.5K | $666.1K |
| Net income | $1.4M | $883.6K | $767.9K | $492.9K |
| EPS (diluted) | 0.11 | 0.07 | 0.06 | 0.04 |
| Operating cash flow | $1.2M | $675.1K | $932.4K | $711.2K |
| Cash | $2.2M | $2.1M | $2.5M | $2.0M |
| Dividends paid | $37.0K | $0 | $1.3M | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
PFHO Stock Sonar score 5/7 axes
Find similar shapesComparePFHO ranks highest on financial health (91st percentile) and insider conviction (71st), and lowest on growth (49th), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PFHO filings, in plain words
Are Pacific Health Care Organization insiders buying or selling PFHO?
In the 180 days to 2026-10-28, Pacific Health Care Organization insiders were net buyers, a net $90.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Pacific Health Care Organization insiders were net buyers of PFHO, a net $90.0K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $90.0K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
